Rheumatoid arthritis (RA) of the hip is an inflammatory joint disease in which the body's immune system attacks the synovial lining of the hip joint, causing chronic inflammation, cartilage destruction, bone erosion, and progressive pain and disability. Unlike osteoarthritis — which is driven by mechanical wear — rheumatoid arthritis is a systemic autoimmune condition that can affect multiple joints simultaneously and requires systemic medical management alongside orthopedic care.
Rheumatoid arthritis of the hip must be distinguished from hip osteoarthritis, which it can closely resemble on clinical examination but differs fundamentally in its inflammatory mechanism, imaging appearance, and treatment approach. Chronic hip RA with persistent synovial inflammation can lead to avascular necrosis (AVN) of the femoral head — both as a direct consequence of the disease and as a complication of long-term corticosteroid use, which is commonly prescribed for RA management. In children and adolescents, juvenile idiopathic arthritis (JIA) is the pediatric counterpart and shares many features with adult RA, including the risk of hip joint destruction if inadequately controlled. Sacroiliac joint involvement — sacroiliitis — is common in related inflammatory arthropathies including ankylosing spondylitis and psoriatic arthritis, which must be considered in the differential diagnosis.
Causes
Autoimmune inflammation.
Rheumatoid arthritis results from a dysregulated immune response in which autoreactive T cells and B cells target synovial tissue as foreign, triggering persistent inflammation. The inflamed synovium (pannus) produces a cascade of pro-inflammatory cytokines — particularly tumor necrosis factor alpha (TNF-?), interleukin-6 (IL-6), and interleukin-1 — that directly damage cartilage and bone. The pannus tissue invades and erodes the articular cartilage and underlying bone, producing the characteristic marginal erosions visible on imaging. The hip joints are involved in approximately 30–40% of patients with RA over the course of their disease, typically following involvement of the smaller joints of the hands and feet. Hip involvement tends to indicate more aggressive systemic disease.
Risk factors.
Rheumatoid arthritis is approximately 2–3 times more common in women than men, with peak onset between ages 40 and 60, though it can occur at any age. Genetic factors — particularly the HLA-DR4 shared epitope — confer significant susceptibility. Cigarette smoking is the strongest modifiable environmental risk factor, roughly doubling the risk of developing seropositive RA. Family history, prior infection with certain pathogens (Epstein-Barr virus, Porphyromonas gingivalis from periodontal disease), and hormonal factors also contribute.
Symptoms
Hip involvement in RA typically presents as deep groin pain, stiffness, and a progressive limp. Morning stiffness lasting more than one hour — a hallmark of inflammatory arthritis that distinguishes it from the brief gelling of osteoarthritis — is characteristic. Pain worsens with activity and weight-bearing and may also be present at rest and at night as the disease progresses. Global restriction of hip range of motion develops as synovial thickening, joint effusion, and cartilage loss accumulate. Unlike osteoarthritis, which typically narrows the joint space superiorly (where loading is greatest), RA tends to cause concentric joint space narrowing — equally in all directions — reflecting diffuse synovial destruction rather than focal wear. Constitutional symptoms including fatigue, low-grade fever, and morning stiffness throughout multiple joints are typically present given the systemic nature of the disease.
Diagnosis
A physical exam by a doctor assesses the pattern of joint involvement, range of motion, gait, and signs of active synovitis — warmth, effusion, and synovial thickening in the groin. Serologic testing including rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (anti-CCP) — the most specific marker for RA — along with inflammatory markers (ESR, CRP) are essential components of the systemic workup. X-rays of the hip in established RA demonstrate the characteristic concentric joint space narrowing, marginal erosions at the femoral head and acetabular rim, periarticular osteopenia, and in advanced disease, axial (medial) migration of the femoral head through a weakened acetabular floor — a pattern called protrusio acetabuli that is rarely seen in osteoarthritis. An MRI is far more sensitive than X-ray for early synovitis and bone damage, demonstrating synovial thickening and enhancement, joint effusion, bone marrow edema, and early erosions before they are visible on plain films — enabling earlier targeted treatment before irreversible structural damage occurs. MRI also identifies concurrent avascular necrosis, which can develop silently in RA patients on long-term corticosteroids and requires prompt separate management.
Disease severity
Doctors assess RA severity using a combination of clinical, laboratory, and imaging findings.
- Mild: Active synovitis with joint pain and stiffness but minimal or no structural damage on imaging. Responds well to conventional disease-modifying therapy (methotrexate). Hip-specific symptoms may be absent or intermittent.
- Moderate: Ongoing synovial inflammation with early joint space narrowing and marginal erosions on X-ray or MRI. Combination disease-modifying or biologic therapy is typically required. Hip pain and functional limitation become more consistent.
- Severe: Advanced joint destruction with significant joint space loss, large erosions, axial femoral head migration (protrusio acetabuli), or femoral head collapse. Hip replacement is often required for adequate pain control and functional restoration.
Treatments
Treatment of RA of the hip requires a coordinated approach between rheumatology — to control systemic disease — and orthopedic surgery when joint damage has progressed beyond the reach of medical management alone.
Medical management (rheumatology-directed): Disease-modifying antirheumatic drugs (DMARDs) are the cornerstone of RA treatment and must be initiated early to prevent irreversible joint damage. Methotrexate remains the anchor drug for most patients. Biologic agents targeting TNF-? (adalimumab, etanercept, infliximab), IL-6 (tocilizumab), or T-cell co-stimulation (abatacept) are added when conventional DMARDs provide inadequate disease control. JAK inhibitors (tofacitinib, baricitinib) are newer targeted synthetic options. Achieving low disease activity or remission with medical therapy significantly slows or halts structural joint damage and is the primary strategy for preserving the hip joint. Corticosteroids provide rapid symptom relief during flares but are used sparingly due to their cumulative adverse effects — including the risk of AVN.
Intra-articular injections.
Corticosteroid injections directly into the hip joint provide targeted anti-inflammatory relief during flares and can meaningfully reduce synovial inflammation when systemic therapy is being optimized. Image guidance with ultrasound or fluoroscopy is preferred for the deep hip joint to ensure accurate placement. Injections are useful adjuncts but do not replace systemic DMARD therapy.
Total hip arthroplasty.
When hip RA has progressed to advanced joint destruction despite optimal medical management — with severe pain, functional limitation, and significant structural damage on imaging — total hip arthroplasty is the recommended surgical treatment. Hip replacement in RA reliably provides excellent pain relief and functional restoration. Surgical planning must account for the unique challenges of RA hip replacement: bone quality is often poor due to chronic inflammation and corticosteroid use, protrusio acetabuli requires specialized acetabular reconstruction with bone grafting, and perioperative management of immunosuppressive medications requires careful coordination with the rheumatologist to balance infection risk against disease flare risk. After surgery, a structured physical therapy program is essential for restoring strength and gait mechanics.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Hip MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.